Akeso Biopharma
Latest round
- Series D
Last raised
- Nov 2019
Total raised
- $215M
Investors
- 18
About Akeso Biopharma
Established in 2012 and based in Zhongshan, China, Akeso Biopharma, Inc. operates as a biopharmaceutical company that provides biopharmaceutical R&D, production and commercialization. The company has many partners, such as Merck Sharp & Dohme, Summit Therapeutics and Dongrui Pharmaceuticals, etc. It has production base located in Guangzhou and Zhongshan and many offices located in Beijing, Shanghai and Nantong, etc. In June 2018, it cooperated with GE to establish the first biologics production plant in South China using GE FlexFactory technology. In April 2020, the company was listed on the Hongkong stock exchange and its stock code is 9926. In August 2021, its product - Anicor® (PD-1 monoclonal antibody, pacamprinizumab injection) was approved for marketing. The company develops ACE platform and bispecific antibody development technology (Tetrabody.2/CD47) and AK117(CD47). Products include Ketanix® and Anicor®. It can apply in patients with oncology, autoimmune, inflammatory and metabolic diseases. The company will plan to develop innovative drugs, promote clinical and establish production base.
Who invested in Akeso Biopharma
18 investors across 4 rounds
See all investors in Akeso Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Akeso Biopharma
Who invested in Akeso Biopharma?
Akeso Biopharma has 18 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Akeso Biopharma raised?
Akeso Biopharma has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Akeso Biopharma last raise money?
Akeso Biopharma's most recent round on record is a Series D, in Nov 2019.
What does Akeso Biopharma do?
Established in 2012 and based in Zhongshan, China, Akeso Biopharma, Inc.
Where is Akeso Biopharma headquartered?
Akeso Biopharma is headquartered in Zhongshan, China.
Which VCs invest in companies like Akeso Biopharma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Akeso Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Akeso Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.